去势治疗诱导的神经内分泌前列腺癌的研究进展  

Research progress on neuroendocrine prostate cancer induced by androgen deprivation therapy

作　　者：杜君[1] 陈倩倩[1] 杨庆[1] 

机构地区：[1]天津医科大学肿瘤医院泌尿肿瘤科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室,天津市300060

出　　处：《中国肿瘤临床》2016年第2期86-88,共3页Chinese Journal of Clinical Oncology

基　　金：国家自然科学青年科学基金项目(编号:81502218)资助~~

摘　　要：转移性前列腺癌行去势治疗(androgen-deprivation therapy,ADT)后将逐渐发展为去势抵抗性前列腺癌(castration-resistant prostate cancer,CRPC)。神经内分泌前列腺癌(neuroendocrine prostate cancer,NEPC)是CRPC的极差预后亚型,多由前列腺癌细胞发生神经内分泌分化(neuroendocrine differentiation,NED)引起,放化疗效果较差,平均生存期不到1年,约占因CRPC患者死亡的25%,目前其分子机制研究较有限。进一步研究NEPC发生的分子机制将为NEPC治疗药物的开发与应用提供新的思路。Patients with metastatic prostate cancer are typically managed with androgen deprivation therapy. Most patients initially respond to treatment, but many eventually develop castration-resistant prostate cancer. Neuroendocrine prostate cancer （NEPC） is a highly aggressive subtype of castration-resistant prostate cancer, which often results from neuroendocrine differentiation of prostate cancer cells. NEPC has a dismal outcome with an average survival of less than 1 year and exhibits less response to radiochemotherapy. At least25% of patients with lethal castration-resistant prostate cancer are predicted to eventually develop this type of highly-aggres-sive NEPC. However, research on the molecular mechanism of NEPC is limited; thus, further studies are needed to explore the develop -ment and application of anticancer drugs for NEPC.

关 键 词：前列腺癌 去势治疗 神经内分泌分化 

分 类 号：R737.25[医药卫生—肿瘤]